Local Recurrence Prediction of by Texture Analysis Derived From Positron Emission Tomography (PET / CT) Imaging of Non-small Cell Lung Cancer (NSCLC) Treated With Stereotactic Radiotherapy (SBRT) (Retros MUMOFRAT) (MUMOFRAT retro)

Local Recurrence Prediction of by Texture Analysis Derived From Positron Emission Tomography (PET / CT) Imaging of Non-small Cell Lung Cancer (NSCLC) Treated With Stereotactic Radiotherapy (SBRT)

The aim of this retrospective multicentric study was to develop and evaluate a prognostic FDG PET/CT radiomics signature in early-stage non-small cell lung cancer (NSCLC) patients treated with stereotactic radiotherapy (SBRT).

Study Overview

• Status: Completed
• Conditions: Identify FDG PET/CT Parameters Predictive of Local Control

• Study Type: Observational
• Enrollment (Actual): 87

Contacts and Locations

Study Locations

• France
  • Brest, France, 29609
    • CHRU de Brest
  • Rennes, France, 35042
    • Centre Eugènes Marquis
  • Tours, France, 37000
    • CHU de Tours
  • Saint Herblain
    • Nantes, Saint Herblain, France, 44800
      • ICO

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Eighty-seven patients with NSCLC stage I-II and tumours diameters below 5 cm according to the 8th American Joint Committee on Cancer classification, treated with definitive curative SBRT from January 2012 to December 2016 at 4 French institutions (Rennes, Tours, Brest and Nantes) were retrospectively included.

Description

Inclusion Criteria:

• NSCLC stage I-II treated by SBRT
• PET/CT imaging performed within 60 days of SBRT

Exclusion Criteria:

• Lack of follow-up
• Refusal of consent

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Local Recurrence	accuracy	Time-to-Event measures up to 5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cancer specific survival	accuracy	Time-to-Event measures up to 5 years
Distant metastasis free survival	accuracy	Time-to-Event measures up to 5 years
Recurrence free survival	accuracy	Time-to-Event measures up to 5 years
Overall survival	accuracy	Time-to-Event measures up to 5 years

Collaborators and Investigators

• Sponsor: University Hospital, Brest

Study record dates

Study Major Dates

• Study Start (Actual): January 7, 2019
• Primary Completion (Actual): February 6, 2019
• Study Completion (Actual): February 6, 2019

Study Registration Dates

• First Submitted: August 13, 2024
• First Submitted That Met QC Criteria: August 13, 2024
• First Posted (Actual): August 15, 2024

Study Record Updates

• Last Update Posted (Actual): August 15, 2024
• Last Update Submitted That Met QC Criteria: August 13, 2024
• Last Verified: December 1, 2018

More Information

Terms related to this study

• Keywords: PET/CT; Stereotactic radiotherapy; Radiomics; Early-stage NSCLC
• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Recurrence
• Other Study ID Numbers: 29BRC18.0283 - Retros MUMOFRAT

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No